Menu
  • Join
  • Login
  • Contact
 

Search abstracts


A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: SOUSA, Flávia (i3S, INEB, Porto, Portugal)
  • Co-author(s): Flávia Sousa: INEB, University of Porto, Porto, Portugal;i3S, University of Porto, Porto, Portugal;, International Iberian Nanotechnology Laboratory, Braga, Portugal;Instituto Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal;, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Porto, Portugal
    Andrea Cruz: International Iberian Nanotechnology Laboratory, Braga, Portugal
    Inês Mendes Pinto: International Iberian Nanotechnology Laboratory, Braga, Portugal
    Maria Teresa Neves-Petersen: Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark
    Bruno Sarmento: INEB, University of Porto, Porto, Portugal;i3S, University of Porto, Porto, Portugal
  • Abstract:

    Backgrounds

    Monoclonal antibodies (mAbs) have deserved a remarkable interest for more than 40 years as a vital tool for the treatment of various diseases. Despite mAbs-based therapy have noteworthy interest, there are some limitations such multiples administrations by the intravenous route, short half-life, and short shelf-life.

    Aims

    Thus, the aim of

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses